Integral Investment Advisors Inc. Takes Position in Moderna, Inc. (NASDAQ:MRNA)

Integral Investment Advisors Inc. bought a new stake in Moderna, Inc. (NASDAQ:MRNA) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 4,819 shares of the company’s stock, valued at approximately $200,000.

Other institutional investors have also modified their holdings of the company. Cohen Capital Management Inc. grew its holdings in Moderna by 22.2% during the fourth quarter. Cohen Capital Management Inc. now owns 10,938 shares of the company’s stock worth $455,000 after acquiring an additional 1,984 shares during the period. Compass Planning Associates Inc acquired a new position in Moderna during the fourth quarter worth $37,000. Prakash Investment Advisors LLC acquired a new position in Moderna during the fourth quarter worth $283,000. ING Groep NV acquired a new position in Moderna during the fourth quarter worth $1,798,000. Finally, Handelsbanken Fonder AB grew its holdings in Moderna by 30.5% during the fourth quarter. Handelsbanken Fonder AB now owns 156,970 shares of the company’s stock worth $6,527,000 after acquiring an additional 36,697 shares during the period. Institutional investors and hedge funds own 75.33% of the company’s stock.

Insider Activity

In other news, insider Shannon Thyme Klinger sold 1,418 shares of the company’s stock in a transaction on Friday, November 29th. The stock was sold at an average price of $42.79, for a total value of $60,676.22. Following the sale, the insider now directly owns 19,717 shares in the company, valued at $843,690.43. This represents a 6.71 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold 2,664 shares of company stock worth $115,210 over the last three months. 15.70% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

MRNA has been the topic of a number of recent analyst reports. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $40.00 price objective on shares of Moderna in a report on Tuesday, February 18th. Argus downgraded Moderna from a “buy” rating to a “hold” rating in a research report on Wednesday, December 18th. Morgan Stanley decreased their target price on Moderna from $70.00 to $38.00 and set an “equal weight” rating on the stock in a research report on Wednesday, January 15th. HSBC upgraded Moderna from a “hold” rating to a “buy” rating and set a $58.00 target price on the stock in a research report on Monday, November 18th. Finally, Barclays downgraded Moderna from an “overweight” rating to an “equal weight” rating and decreased their target price for the stock from $111.00 to $45.00 in a research report on Tuesday, February 18th. Four research analysts have rated the stock with a sell rating, fifteen have given a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Moderna presently has a consensus rating of “Hold” and a consensus target price of $60.63.

Moderna Stock Up 5.3 %

Shares of NASDAQ:MRNA opened at $35.53 on Friday. Moderna, Inc. has a 52-week low of $29.25 and a 52-week high of $170.47. The stock’s fifty day simple moving average is $38.04 and its 200-day simple moving average is $52.66. The company has a market capitalization of $13.67 billion, a P/E ratio of -3.83 and a beta of 1.59.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.